NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"
NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"
The purpose of this study is to evaluate the safety of NINLARO in participants with
 relapsed/refractory multiple myeloma in daily clinical practice.
The drug being tested in this study is called Ixazomib (NINLARO). Ixazomib is being tested to
 treat people who have relapsed/refractory multiple myeloma. This study will look at the
 safety of NINLARO in participants with relapsed/refractory multiple myeloma in daily clinical
 practice.

 The study will enroll approximately 480 patients.

 • Ixazomib 4 mg

 This multi-center trial will be conducted in Japan.
Inclusion Criteria:

 -  All patients who have been confirmed as administration of the drug.

 Exclusion Criteria:

 -  None